Cardiomyopathy in a dog with multicentric lymphoma following treatment with several anthracyclines

• Published in: Open veterinary journal (Tripoli, Libya) Vol. 11; no. 1; pp. 6 - 10
• Main Authors: Tagawa, Michihito, Shimbo, Genya, Uemura, Akiko, Matsumoto, Kotaro
• Format: Journal Article
• Language: English
• Published: Libya Faculty of Veterinary Medicine 01.01.2021; Tripoli University
• Subjects: aicm; anthracycline-induced cardiomyopathy; Case Report; dog; lymphoma; AICM; Dog; Lymphoma; Anthracycline-induced cardiomyopathy
• ISSN: 2226-4485; 2218-6050; 2218-6050
• DOI: 10.4314/ovj.v11i1.2

Canine lymphoma is one of the most frequently occurring malignant neoplasms in dogs. Anthracycline-based chemotherapy for the treatment of canine lymphoma is very effective; however, there is not enough evidence for the development of cardiac toxicity using several anthracyclines as chemotherapeutic agents. An 8-year-old, castrated, mixed-breed dog was diagnosed with multicentric lymphoma and received multi-agent chemotherapy. Complete remission was achieved, but the patient had a relapse of lymphoma. After third-line chemotherapy with epirubicin, the patient was diagnosed with dilated cardiomyopathy. The total cumulative doses of doxorubicin, mitoxantrone, and epirubicin were 125, 8, and 125 mg/m , respectively. Although the patient was treated with cardiac drugs and clinically stabilized, the patient had a relapse of lymphoma and died shortly after the diagnosis of cardiomyopathy. The patient was suspected to have anthracycline-induced cardiomyopathy. Further studies are required to establish prevention and management strategies for dogs receiving potentially cardiotoxic therapies, such as anthracyclines.